Ginseng-Derived Nanovesicles Suppress Liver Fibrosis via TIMP2 Pathway Modulation and Gut Microbiota balance.
Young-Eun Cho – professor, Gyeongkuk National University; Do-Kyun Kim – professor, Kora Zoonosis Research Institute; Jae-Hee Kwon – Ph.D. candidate, Gyeongkuk National University; Bum-Joon Koo – Master student, Gyeongkuk National University
Post Doctor Gyeongkuk National University, Republic of Korea
Introduction: Metabolic dysfunction-associated fatty liver disease (MASLD) and alcohol-associated liver disease (ALD) are prevalent chronic liver diseases that can progress to steatohepatitis, fibrosis, cirrhosis, and ultimately liver failure (1). Plant-derived exosome-like nanovesicles have emerged as promising therapeutic agents, but the potential benefits of ginseng-derived exosome-like nanovesicles (GNVs) in MASLD and ALD remain largely unexplored. With limited pharmacologic options and key roles for inflammation, oxidative stress, and the gut–liver axis, safe vesicle-based interventions are needed.
Learning Objectives:
Explain how GNVs improve the gut–liver axis in MASLD and ALD.
Summarize their effects on liver steatosis, oxidative stress, and fibrosis.
Describe their safety/oral stability and the proposed TIMP-2–related mechanism.
